R D Burman death anniversary | On compositions of pathos, reflections and sadness

Rahul Dev Burman, or ‘Pancham Da’ or ‘Boss’, as he was fondly called, is often credited with changing the sound of Hindi film ...
pharmaphorum

Pathos AI's big $365m Series D, and other bio financings

In another signal of the appetite among investors for companies applying artificial intelligence to drug discovery, Pathos AI has gathered an impressive $365 million in fourth-round financing as it ...
This is Money

London PR firm Pathos pitches listing for December

A British marketing agency ranked among Europe's fastest-growing businesses is planning to float on the London Stock Exchange later this month, The Mail on Sunday understands. Pathos Communications, ...
London South East

Schedule One - Pathos Communications plc

TBC - website address containing all information required by AIM Rule 26 will be confirmed in due course and be made live on admission Pathos is a technology-enabled ...
The Canberra Times

Pathos Communications Reviews: To trust or not to trust?

Increased global competition has fuelled disruption and competition in almost all industries. There are notable exceptions, however, where businesses are not spoilt for choice. One of those is in the ...
SiliconANGLE

AI-powered drug development startup Pathos AI closes $365M investment

Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding. The company didn’t disclose the ...
Crain's Chicago Business

Pathos raises $365 million in funding round, touts $1.6 billion valuation

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pathos AI, the biotech drug developer spun out of Tempus ...
FierceBiotech

Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug

Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics. The ...
Yahoo Finance

Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-driven biotech company applying cutting-edge artificial intelligence to drug development, today announced its $365 million Series D ...
Benzinga.com

Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model

Tempus AI Inc. (NASDAQ:TEM) during the first quarter secured a multi-million dollar deal to build “the world’s largest foundation model for oncology.” “And this is big for a few reasons,” said Tempus ...
Crain's Chicago Business

Tempus exec-founded Pathos AI launched a $400M funding round. It's already filling up.

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pathos AI has launched a $400 million funding round and ...
pharmaphorum

AstraZeneca joins Tempus, Pathos in cancer AI project

AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and comprehensive generative artificial intelligence model for oncology. The ...